Starlix

Starlix can help lower blood sugar levels in people with type 2 diabetes. It causes the pancreas to produce more insulin and lower blood sugar levels after meals. The medication comes in tablet form, and can be taken up to half an hour before each meal. Side effects are possible, such as low blood sugar, flu-like symptoms, and dizziness.

What Is Starlix?

Starlix® (nateglinide) is a prescription medication that is used to treat type 2 diabetes (also known as non-insulin-dependent diabetes or adult-onset diabetes).
 
(Click Starlix Uses for more information, including possible off-label uses.)
 

Who Makes It?

Starlix is manufactured by Novartis Pharmaceuticals.
 

How Does Starlix Work?

Starlix is part of a group of diabetes medications called meglitinides. A meglitinide helps the pancreas make more insulin, which helps to lower blood sugar. Another type of diabetes medications, called sulfonylureas (see Starlix Alternatives), also helps the pancreas make more insulin. However, unlike sulfonylureas, Starlix is short-acting and is used to lower blood sugar levels after meals.
 

Clinical Effects

Several studies have looked at the effects of Starlix, particularly with regards to hemoglobin A1c and fasting blood sugar.
 
 
Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. For people without diabetes, HbA1c results are usually less than 6 percent, while people with diabetes usually have higher results. In one study, people taking Starlix lowered their HbA1c by up to 0.5 percent, on average, while people not taking the drug increased their HbA1c by 0.2 percent.
 
Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes. This includes problems such as:
 
 
By getting blood sugar levels under control with Starlix, it may be possible to decrease the chances of developing these diabetes-related complications.
Starlix Article Continues on Next Page >
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD
Other Articles in This eMedTV Presentation